| Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer (NCT02996825) | City of Hope Medical Center | 2017-03-22 |
| Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer (NCT02684227) | M.D. Anderson Cancer Center | 2016-08-24 |
| Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer (NCT02657928) | Mayo Clinic | 2016-07-08 |
| Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies (NCT02578888) | Albert Einstein College of Medicine | 2015-04-01 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (NCT02208375) | M.D. Anderson Cancer Center | 2014-11-11 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (NCT01970722) | City of Hope Medical Center | 2014-05-19 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer (NCT02065687) | Gynecologic Oncology Group | 2014-03-17 |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01642082) | Gynecologic Oncology Group | 2012-09-01 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01225887) | Gynecologic Oncology Group | 2011-10-01 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (NCT01440998) | National Cancer Institute (NCI) | 2011-09-20 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer (NCT01307631) | National Cancer Institute (NCI) | 2011-03-01 |
| Prognostic Biomarkers in Patients With Endometrial Cancer (NCT01208467) | Gynecologic Oncology Group | 2010-09-01 |
| Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer (NCT01098630) | Gynecologic Oncology Group | 2010-07-01 |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01132820) | National Cancer Institute (NCI) | 2010-06-01 |
| Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT01164735) | Gynecologic Oncology Group | 2010-01-01 |
| Biomarkers in Samples From Patients With Endometrial Cancer (NCT01199250) | Gynecologic Oncology Group | 2010-01-01 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (NCT01010126) | National Cancer Institute (NCI) | 2009-09-08 |
| Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01011933) | National Cancer Institute (NCI) | 2009-09-01 |
| Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00820898) | Gynecologic Oncology Group | 2009-02-01 |
| Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer (NCT00729586) | National Cancer Institute (NCI) | 2008-09-01 |
| Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (NCT00575952) | Gynecologic Oncology Group | 2008-01-17 |
| Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (NCT00478426) | National Cancer Institute (NCI) | 2007-04-30 |
| Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery (NCT00410553) | National Cancer Institute (NCI) | 2006-11-14 |
| Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer (NCT00006903) | Gynecologic Oncology Group | 2004-08-30 |
| Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus (NCT00064025) | Gynecologic Oncology Group | 2004-04-01 |
| Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (NCT00063999) | GOG Foundation | 2003-08-25 |
| Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer (NCT00027690) | National Cancer Institute (NCI) | 2002-06-01 |
| Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00006089) | National Cancer Institute (NCI) | 2000-09-18 |
| Collecting Tumor Samples From Patients With Gynecological Tumors (NCT00897442) | Gynecologic Oncology Group | 1992-06-01 |